Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Recommendations for Hep C Virus testing of persons born during 1945–1965

This month's Annals of Internal Medicine reports on recommendations from the Centers for Disease Control and prevention Hepatitis C virus testing of persons born during 1945–1965.

News image

The Centers for Disease Control and Prevention developed these evidence-based recommendations to increase the proportion of hepatitis C virus (HCV)–infected persons who know their status and are linked to appropriate care and treatment.

They recommend that adults born during 1945–1965 receive 1-time testing for HCV without prior ascertainment of HCV risk.

The team report that all persons identified with HCV infection receive a brief alcohol screening and intervention as clinically indicated, followed by referral to appropriate care and treatment services for HCV infection and related conditions as indicated.

The Centers for Disease Control and Prevention (CDC) estimates that 3.4 to 4.9 million persons have ever been infected with hepatitis C virus (HCV) in the United States.

All of these persons develop HCV antibodies, and approximately 75% develop a chronic infection.

This results in an estimated 2.7 to 3.9 million persons living with HCV infection in the United States.

Incidence of HCV increased markedly during the 1970s and 1980s, reaching an average of 230,000 new infections each year throughout the 1980s.

Incidence declined rapidly in the 1990s because of effective screening of blood donors starting in 1992, and reduced numbers of new infections among persons who inject drugs.

The CDC reports that the incidence declined until 2006 and has since remained stable, with an estimated 17,000 new infections in 2010.

Those who were infected in the remote past have been living with HCV infection for 20 to 40 years and are at increased risk for HCV-related morbidity and mortality.

Hepatitis C virus infection is the leading indication for liver transplantation, and accounts for more than 50% of incident hepatocellular carcinoma.

The team reports that the fastest-growing cause of cancer-related death in the United States.

The team noted that annual HCV-associated mortality in the United States increased over 50% from 1999 to 2007.

Data from death certificates show that HCV-associated deaths are now more frequent than deaths caused by HIV.

Modeling studies forecast substantial increases in morbidity and mortality among HCV-infected persons as they enter into their third, fourth, and fifth decades of living with infection.

The CDC estimates that without diagnosis and treatment 1.76 million persons with HCV infection will develop cirrhosis during their lifetimes, over 400,000 will develop HCC, and over 1 million will die from HCV-associated disease.

In 1998, the CDC issued recommendations for identifying HCV-infected persons.

Testing for HCV was recommended for persons most likely to be infected, including those who had ever injected drugs, received clotting factor concentrates produced before 1987, ever received long-term hemodialysis, had laboratory evidence of liver disease, or received transfusions of blood or blood components or organ transplants before 1992.

Screening also was recommended for persons who had a recognized blood exposure.

In 1999, HCV testing was recommended for persons infected with HIV.

The success of risk-based testing strategies has been limited.

Depending on the level of risk in the population and site-specific testing practices, an estimated 45% to 85% of U.S. adults are chronically infected with HCV yet unaware of their condition.

Testing for HCV seromarkers is suboptimal even among high-risk populations for whom routine testing is recommended.

The CDC notes that a sizeable percentage of these persons remain unaware of their infection status.

Dr Smith and colleagues conclude, "Because of the limited effectiveness of the current HCV testing recommendations alone in identifying undiagnosed infections, the CDC considered a birth year–based HCV testing strategy to increase the proportion of infected persons who know their HCV infection status."

"1-time HCV testing of persons born during 1945–1965."

"These persons account for 76.5% of all prevalence of those with HCV antibodies."

"Because alcohol accelerates progression of liver disease in HCV-infected persons, the CDC also addressed brief alcohol screening for those with HCV infection."

Ann Intern Med 2012; 157(11): 817-822
07 December 2012

Go to top of page Email this page Email this page to a colleague

 31 October 2014

Advanced search
 31 October 2014 
C. difficile infection with metronidazole
 31 October 2014 
Pediatric NAFLD
 31 October 2014 
Pregnancy complications in celiac disease
 30 October 2014 
Constipation and colorectal cancer
 30 October 2014 
Costs in newly diagnosed patients with chronic constipation
 30 October 2014 
Cirrhosis in women
 29 October 2014 
Quality of life after infection with E. coli
 29 October 2014 
IBS in primary care
 29 October 2014 
Sensorimotor activity in functional dyspepsia
 28 October 2014 
Risk factor for smaller final height in Crohn's
 28 October 2014 
Increased bile acid synthesis in IBS-diarrhea
 28 October 2014 
Successful radiofrequency ablation for Barrett’s
 27 October 2014 
Celiac disease and type 1 diabetes
 27 October 2014 
Gluten awareness among chefs
 27 October 2014 

PPI-responsive esophageal eosinophilia

 24 October 2014 
Olmesartan-associated enteropathy
 24 October 2014 
Opioid use in IBD
 24 October 2014 
NSAIDs and Barrett's risk
 23 October 2014 
Outcomes in hospitalized patients with GI bleeding
 23 October 2014 
Thiopurines and colorectal cancer risk in IBD
 23 October 2014 
Advancing the field of functional GI disorders
 22 October 2014 
Early-TIPSS placement prevents rebleeding
 22 October 2014 
Liver fibrosis prognostic biomarkers in type-2 diabetes
 22 October 2014 
H pylori eradication with multiple drug resistance
 21 October 2014 
Alcohol and Barrett's
 21 October 2014 
Scoring systems for critically ill cirrhotic patients
 21 October 2014 
Aspirin and NAFLD
 20 October 2014 
Adalimumab in secondary loss of response in Crohn's
 20 October 2014 
Drug resistant H pylori eradication
 20 October 2014 
Omega-3 and colorectal cancer
 17 October 2014 
Tumor necrosis factor-alpha inhibitors and pregnancy in IBD
 17 October 2014 
Colorectal testing utilization
 17 October 2014 
Fecal microbiota composition in postinfectious IBS
 16 October 2014 
Risk of Barrett's esophagus
 16 October 2014 
Aspirin tablets and colorectal tumours
 16 October 2014 
Economic impact of IBS
 15 October 2014 
Achieving competency at colonoscopy
 15 October 2014 
Preparation for surgery in Crohn's
 15 October 2014 
Bowel preparations
 14 October 2014 
Colorectal testing utilization in commercially insured US adults
 14 October 2014 
Sustained response to infliximab
 14 October 2014 
IBD management during pregnancy
 13 October 2014 
Predicting PPI response in GERD-related cough
 13 October 2014 
Probiotics in IBS
 13 October 2014 
Use of azathioprine in IBD
 10 October 2014 
NAFLD in the Veterans Administration population
 10 October 2014 
Liver injury from herbals and dietary supplements
 10 October 2014 
Predictors for cecal insertion time
 09 October 2014 
Methotrexate-related liver disease and metabolic syndrome
 09 October 2014 
Biomarkers of acetaminophen overdose patients
 09 October 2014 
Postoperative adhesions in digestive surgery
 08 October 2014 
Gluten introduction in high risk children
 08 October 2014 
Vitamin D and HCC
 08 October 2014 
Feeding intervention in celiac disease infants
 07 October 2014 
Infliximab in pediatric perianal Crohn's
 07 October 2014 
Omega-3 and NAFLD
 07 October 2014 
Endoscopic submucosal dissection in the colorectum 
 06 October 2014 
Clinical indications for computed tomographic colonography
 06 October 2014 
Certolizumab pegol in the treatment of Crohn's
 06 October 2014 
Costs of telaprevir therapy for Hep C

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us